NASDAQ:RGNXRegenxbio Stock Price, Forecast & News

Regenxbio's stock was trading at $32.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RGNX shares have increased by 17.5% and is now trading at $38.65. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regenxbio in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Regenxbio.

Regenxbio is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Regenxbio.

Regenxbio Inc (NASDAQ:RGNX) posted its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.87) by $0.21. The biotechnology company had revenue of $17.60 million for the quarter, compared to analyst estimates of $17.99 million. Regenxbio had a negative net margin of 197.23% and a negative return on equity of 27.84%. The company's revenue for the quarter was up 1855.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.89) earnings per share. View Regenxbio's earnings history.

6 brokers have issued 1-year target prices for Regenxbio's shares. Their forecasts range from $37.00 to $150.00. On average, they expect Regenxbio's stock price to reach $68.33 in the next year. This suggests a possible upside of 76.8% from the stock's current price. View analysts' price targets for Regenxbio.

Press coverage about RGNX stock has trended somewhat positive this week, InfoTrie reports. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Regenxbio earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View the latest news about Regenxbio.

Some companies that are related to Regenxbio include Novavax (NVAX), Acceleron Pharma (XLRN), Allogene Therapeutics (ALLO), Crispr Therapeutics (CRSP), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Momenta Pharmaceuticals (MNTA), Ablynx (ABLYF), Halozyme Therapeutics (HALO), Iovance Biotherapeutics (IOVA), bluebird bio (BLUE), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Twist Bioscience (TWST) and Immunovant (IMVT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Regenxbio investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Voyager Therapeutics (VYGR), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Amarin (AMRN), QUALCOMM (QCOM), Bristol-Myers Squibb (BMY) and Square (SQ).

Regenxbio trades on the NASDAQ under the ticker symbol "RGNX."

Regenxbio's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Exane Derivatives (0.01%). Company insiders that own Regenxbio stock include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Luke M Beshar, Olivier Danos, Patrick J Christmas, Stephen Yoo and Vittal Vasista. View institutional ownership trends for Regenxbio.

RGNX stock was bought by a variety of institutional investors in the last quarter, including Exane Derivatives. View insider buying and selling activity for Regenxbio.

Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RGNX stock can currently be purchased for approximately $38.65.

Regenxbio has a market capitalization of $1.44 billion and generates $35.23 million in revenue each year. The biotechnology company earns $-94,730,000.00 in net income (profit) each year or ($3.26) on an earnings per share basis. Regenxbio employs 192 workers across the globe.

The official website for Regenxbio is www.regenxbio.com.

Regenxbio's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-552-8181 or via email at [email protected]